Medical disclaimer
Ropeginterferon alfa-2b vs hydroxyurea in early polycythemia vera: research by Vienna clinic doctor
9 min read
Prepared by Bookimed editorial team
Medical content and care coordination

The named clinic is an author affiliation. The study patients were not established as patients treated at that clinic.
Key takeaways
- The trial compared ropeginterferon alfa-2b with hydroxyurea in adults with early polycythemia vera; 127 patients were treated in each group.
- At 12 months, 26 of 122 patients on ropeginterferon alfa-2b and 34 of 123 on hydroxyurea had a complete hematological response with normal spleen size, and non-inferiority was not shown.
- At 36 months, 50 of 95 patients on ropeginterferon alfa-2b and 28 of 74 on hydroxyurea had a complete hematological response with improved disease burden.
- Serious treatment-related adverse events occurred in three of 127 patients on ropeginterferon alfa-2b and five of 127 on hydroxyurea.
- These are group results from a trial and are not a forecast for any individual patient.
The question this study addresses
PROUD-PV and its extension CONTINUATION-PV were randomized, open-label phase 3 trials run in 48 clinics in Europe from 2013 to 2015 recruitment. They compared ropeginterferon alfa-2b with hydroxyurea, the standard therapy, over 3 years of treatment. The patients were treated at those European clinics and not at Confraternitaet & Goldenes Kreuz Private Clinic. Heinz Gisslinger, a hematologist at Medical University Vienna, is an author of the paper and now practices at the clinic according to the Bookimed profile. The study was funded by AOP Orphan Pharmaceuticals AG, and Bookimed did not run it.
- The situation
- Adults aged 18 or older with early polycythemia vera, meaning no history of cytoreductive treatment or less than 3 years of previous hydroxyurea treatment, diagnosed by the WHO 2008 criteria.
- The treatment
- Ropeginterferon alfa-2b by subcutaneous injection every 2 weeks, starting at 100 μg, compared with oral hydroxyurea starting at 500 mg/day.
What this evidence cannot establish
- The patients were treated at 48 clinics in Europe, not at Confraternitaet & Goldenes Kreuz Private Clinic, so the results do not describe that clinic's own patients.
- The trials were open-label, analyses were per-protocol, and the 36-month CONTINUATION-PV results are an interim analysis of a trial that is ongoing.
- Most patients presented without splenomegaly, and the abstract does not give molecular response figures.
Patient groups in the published study
127 patients · Published study group
Early polycythemia vera treated with ropeginterferon alfa-2b
- Indication
- Early polycythemia vera
- Treatment
- Ropeginterferon alfa-2b subcutaneously every 2 weeks, starting at 100 μg
127 adult patients treated in the ropeginterferon alfa-2b group.
Adults with early polycythemia vera who had no cytoreductive treatment before, or less than 3 years of hydroxyurea.
Injections under the skin every 2 weeks starting at 100 μg, with an option to continue in the extension study after 1 year.
Composite primary endpoint: complete haematological response with normal spleen size (PROUD-PV, 12 months)
26 / 122
122 patients · Study group
12 months
Complete haematological response without the spleen criterion (PROUD-PV, 12 months)
53 / 123
123 patients · Study group
12 months
Complete haematological response with improved disease burden (CONTINUATION-PV, 36 months)
50 / 95
95 patients · Study group
36 months
Complete haematological response without the spleen criterion (CONTINUATION-PV, 36 months)
67 / 95
95 patients · Study group
36 months
Grade 3-4 treatment-related increased alanine aminotransferase
4 / 127
127 patients · Study group
not stated
Treatment-related serious adverse events
3 / 127
127 patients · Study group
not stated
Reported risks
- Study-wide item: grade 3 and 4 treatment-related increased alanine aminotransferase occurred in four of 127 patients in this group, and treatment-related serious adverse events in three of 127.
Limits of this evidence
- Outcomes are per-protocol, and the denominators differ between endpoints.
- Molecular response figures are not given in the abstract.
For a clinic assessment
- Current hematology report and blood counts with the polycythemia vera diagnosis.
- List of previous treatments, including any hydroxyurea and its duration.
127 patients · Published study group
Early polycythemia vera treated with hydroxyurea (standard therapy)
- Indication
- Early polycythemia vera
- Treatment
- Hydroxyurea orally, starting at 500 mg/day
127 adult patients treated in the hydroxyurea comparison group.
The same early polycythemia vera population, randomly assigned 1:1 to the standard therapy.
Oral hydroxyurea starting at 500 mg/day.
Composite primary endpoint: complete haematological response with normal spleen size (PROUD-PV, 12 months)
34 / 123
123 patients · Study group
12 months
Complete haematological response without the spleen criterion (PROUD-PV, 12 months)
57 / 125
125 patients · Study group
12 months
Complete haematological response with improved disease burden (CONTINUATION-PV, 36 months)
28 / 74
74 patients · Study group
36 months
Complete haematological response without the spleen criterion (CONTINUATION-PV, 36 months)
38 / 74
74 patients · Study group
36 months
Grade 3-4 treatment-related leucopenia
6 / 127
127 patients · Study group
not stated
Grade 3-4 treatment-related thrombocytopenia
5 / 127
127 patients · Study group
not stated
Treatment-related serious adverse events
5 / 127
127 patients · Study group
not stated
Reported risks
- Study-wide item: grade 3 and 4 treatment-related leucopenia occurred in six of 127 patients and thrombocytopenia in five of 127 in this group; treatment-related serious adverse events occurred in five of 127.
Limits of this evidence
- Three patients withdrew consent in this group.
- Molecular response figures are not given in the abstract.
For a clinic assessment
- Recent blood count results and spleen size measurement, if available.
- Medication list with doses and dates for the coordinator to share with the clinic.
Results and limits of the study
At 12 months in PROUD-PV, 26 of 122 patients on ropeginterferon alfa-2b (21%) and 34 of 123 on hydroxyurea (28%) met the composite endpoint of complete hematological response with normal spleen size, and non-inferiority was not shown. Without the spleen criterion, the figures were 53 of 123 (43%) and 57 of 125 (46%). At 36 months in CONTINUATION-PV, complete hematological response with improved disease burden was met by 50 of 95 patients (53%) on ropeginterferon alfa-2b and 28 of 74 (38%) on hydroxyurea. Without the spleen criterion, 67 of 95 (71%) and 38 of 74 (51%) responded. The authors conclude that responses to ropeginterferon alfa-2b kept increasing over time.
Risks reported by the source
- Increased gamma-glutamyltransferase at grade 3 or 4 occurred in seven of 127 patients and increased alanine aminotransferase in four of 127 on ropeginterferon alfa-2b.
- Leucopenia at grade 3 or 4 occurred in six of 127 patients and thrombocytopenia in five of 127 on hydroxyurea.
- One treatment-related death (acute leukaemia) was reported in the hydroxyurea group.
Limitations and unknowns
- The abstract does not give molecular response figures.
- Results beyond the 36-month interim analysis are not reported, because CONTINUATION-PV is ongoing.
- Per-protocol analysis may not reflect every patient who started treatment.
- The abstract does not say how the results apply to patients with advanced disease or longer prior treatment.
What to clarify in your treatment plan
Before booking, ask the clinic whether the doctor sees patients with early polycythemia vera and whether ropeginterferon alfa-2b is offered at the clinic. Clarify which records the doctor needs, how follow-up and blood monitoring would be arranged, and how care would continue after you return home.
Confraternitaet & Goldenes Kreuz Private Clinic: clinic profile
- The study patients were treated at 48 clinics in Europe, not at Confraternitaet & Goldenes Kreuz Private Clinic.
- Study author Heinz Gisslinger now practices at the clinic in Vienna according to the Bookimed profile.
- The clinic's profile is available on Bookimed.

Confraternitaet & Goldenes Kreuz Private Clinic
Vienna, Austria
3.8/5 · 8 Bookimed reviews (current clinic profile)
Heinz Gisslinger: doctor profile
- Heinz Gisslinger is an author of the paper and works in the Division of Haematology and Blood Coagulation, Department of Internal Medicine I, Medical University Vienna.
- His hematology and polycythemia vera background fits this ropeginterferon paper.

Safety and recovery: general information
General patient guidance, provided separately from the case evidence. Follow your treating team's instructions.
Possible side effects
- Medical sources on immunotherapy list mild side effects such as fatigue, itchy rash, diarrhea, nausea and vomiting, and decreased thyroid hormone levels.
Ask the doctor which of these can apply to your treatment and how they would be monitored.
- Immune cells may attack healthy tissue and cause inflammation that can show up as one or more side effects.
Report new symptoms to your care team rather than waiting.
- Side effects may be serious and even life-threatening.
Discuss the warning signs and the emergency plan before starting.
Recovery and aftercare
- Most side effects are temporary, but in rare cases they can cause long-term effects and may linger after the medicine is out of your system.
Ask how long follow-up lasts.
- Treatment can last a long time, and side effects can occur at any point during and after treatment.
Plan for ongoing monitoring and a local contact.
Suitability and cautions
- You may be more likely to have a side effect if you take a combination of immunotherapy drugs or have an autoimmune disease.
List all your medicines and conditions for the doctor.
- If you have an autoimmune disease, it is especially important to discuss it with your health care provider before starting treatment.
Share your full history before booking.
When to contact the clinic
- Hepatitis can cause jaundice, dark-colored urine, stomach pain on the right side, vomiting, and increased chances of bleeding or bruising.
Contact your doctor promptly if these appear.
- Colitis can cause diarrhea, bloody, dark or tarry stools, and stomach pain.
Contact your doctor promptly if these appear.
- Lung inflammation (pneumonitis) can cause shortness of breath and a bad cough.
Seek advice at once if breathing becomes difficult.
- Your oncologist may advise you to call first about inflammatory symptoms, or to seek emergency medical care.
Ask the clinic which route to follow.
Request a personal plan from the clinic
Ask Confraternitaet & Goldenes Kreuz Private Clinic about care for early polycythemia vera
Bookimed's coordinator can pass your medical records to the clinic and ask whether the doctor can review your case. The clinic then confirms what it can offer.
Ask the clinic for a current, itemized quotation. Published evidence does not establish package inclusions or a current price.
Frequently asked questions
Who ran this study and where were the patients treated?
The study was run by investigators at 48 clinics in Europe and funded by AOP Orphan Pharmaceuticals AG. The patients were treated at those clinics, not at Confraternitaet & Goldenes Kreuz Private Clinic. Author Heinz Gisslinger works at Medical University Vienna and now practices at the clinic according to his Bookimed profile. Bookimed did not run the study.
Was ropeginterferon alfa-2b better than hydroxyurea?
Not at 12 months, but results favored it at 36 months. At 12 months non-inferiority on complete hematological response with normal spleen size was not shown: 26 of 122 patients versus 34 of 123. At 36 months, 50 of 95 patients on ropeginterferon alfa-2b versus 28 of 74 on hydroxyurea had a complete response with improved disease burden. These are group results from the trial.
What side effects were reported in the study?
Serious treatment-related adverse events occurred in three of 127 patients on ropeginterferon alfa-2b and five of 127 on hydroxyurea. The most frequent grade 3 and 4 events were increased gamma-glutamyltransferase (seven patients) and increased alanine aminotransferase (four) with ropeginterferon alfa-2b, and leucopenia (six) and thrombocytopenia (five) with hydroxyurea. One treatment-related death from acute leukaemia occurred in the hydroxyurea group.
Does this study predict my own result?
No. The study reports average group results for adults with early polycythemia vera, analyzed per-protocol, and it cannot forecast an individual outcome. The 36-month data are an interim analysis of a trial that is ongoing. Your own situation, previous treatment and blood counts matter, so review them with a hematologist before deciding on any treatment.
Sources and scope
This page was prepared from the published abstract of the study and its structured results, with the clinic relation checked against the author affiliations. Safety information paraphrases medical sources on immunotherapy and is not taken from the study.
- 1. Gisslinger et al. – Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Randomized, open-label, multicenter phase 3 trial with extension · 2020
257 adults with early polycythemia vera randomly assigned to ropeginterferon alfa-2b or hydroxyurea in 48 European clinics
Follow-up: Median 182·1 weeks (ropeginterferon alfa-2b) and 164·5 weeks (hydroxyurea); interim analysis at 36 months
Only the abstract was used, so details of methods, subgroups and molecular responses are not covered.
- 2. Cleveland Clinic
- 3. National Cancer Institute
- 4. National Cancer Institute
- 5. Confraternitaet & Goldenes Kreuz Private Clinic on Bookimed
- 6. Heinz Gisslinger on Bookimed
Scope and limitations
- A research summary is not an individual medical recommendation.
- Group results describe the study participants, not a forecast for any one patient.
About the editorial team

Prepared by
Bookimed editorial teamMedical content and care coordination
Bookimed prepares evidence summaries from published medical sources and anonymized care records. The clinic and any doctors named on this page are identified separately in their own sections.